<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03109626</url>
  </required_header>
  <id_info>
    <org_study_id>CE NP1821</org_study_id>
    <nct_id>NCT03109626</nct_id>
  </id_info>
  <brief_title>Docosahexaenoic Acid (DHA) Replacement for Treatment in Spinocerebellar Ataxia 38</brief_title>
  <acronym>SCA38DHA</acronym>
  <official_title>Translating Molecular Pathology Into a Therapeutic Strategy in SCA38, a Newly Identified Form of Spinocerebellar Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Borroni</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project will study a therapeutic approach in Spinocerebellar Ataxia (SCA38) by DHA&#xD;
      replacement. SCA38 is caused by missense mutations in the ELOVL5 (Elongation of very long&#xD;
      chain fatty acids protein 5) gene.&#xD;
&#xD;
      Background/Rationale: ELOVL5 is a microsomal fatty acid elongase gene required for the&#xD;
      synthesis of arachidonic acid and DHA. In brain, it shows a peculiar high expression in&#xD;
      cerebellar Purkinje cells.&#xD;
&#xD;
      The ELOVL5 products, such as DHA, are decreased in SCA38 patients serum and DHA administered&#xD;
      as a dietary supplement has been shown to improve SARA scores, to ameliorate quality of life,&#xD;
      and to increase brain cerebellar hypometabolism (FDG-PET) in two SCA38 patients.&#xD;
&#xD;
      Experimental Plan: The investigators will perform a randomized placebo-controlled trial by&#xD;
      DHA supplementation on ten SCA38 patients, followed by an open-label phase.&#xD;
&#xD;
      Expected results: DHA supplementation should be able to improve symptoms in SCA38 and to&#xD;
      improve cerebellar hypometabolism in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spinocerebellar ataxias (SCAs) include over thirty different subtypes of central nervous&#xD;
      system diseases that affect approximately 1 in 30,000 persons. The investigators have&#xD;
      identified the causative gene for SCA38, a novel rare form of cerebellar ataxia. Estimated&#xD;
      frequency of the disease is below 1% of SCAs. The disease gene encodes an enzyme involved in&#xD;
      omega-3 fatty acid biosynthesis, whose products are reduced in SCA38 patients' serum.&#xD;
&#xD;
      The investigators reasoned that the administration of specific omega-3 fatty acids could&#xD;
      ameliorate the disease symptoms in SCA38 patients. Indeed, preliminary data obtained in a&#xD;
      pilot trial on two patients, now in their 8th-month therapy, are remarkable, with an&#xD;
      improvement of disease symptoms and quality of life, without any adverse effect.&#xD;
&#xD;
      The investigators will perform a clinical trial to prove this therapeutic strategy of SCA38.&#xD;
      The investigators will evaluate clinical SARA scores, ICARS scores, brain PET images, and&#xD;
      plasma metabolic pattern in ten SCA38 patients.&#xD;
&#xD;
      The trial will consist of two phases: 1) a randomized double-blind placebo/treatment (600 mg&#xD;
      DHA/day) from T0 (baseline observation) to T1 (evaluation at four-month). Patients who will&#xD;
      meet the study eligibility criteria will be randomized to receive the drug or the placebo&#xD;
      (ratio 1:1). A second open-label phase on all patients from T2 (6 months) to T5 (30 months)&#xD;
      will be performed with repeated measures of the medication group (n=10).&#xD;
&#xD;
      Patients will complete a personal diary during the whole treatment and a quality of life&#xD;
      questionnaire at each visit. The primary outcome will be the clinical improvement, whilst&#xD;
      secondary outcome will be considered the improvement of brain metabolism by PET-FDG.&#xD;
&#xD;
      At each time point, clinical evaluation (video-record of SARA/ICARS scores) will be&#xD;
      performed. Videos will be randomized and evaluated blindly by two independently clinicians.&#xD;
&#xD;
      At T0, T1, T2, T5, patients will undergo brain PET-FDG scan. PET-FDG scans will be performed&#xD;
      by the same scanner at the University of Brescia.&#xD;
&#xD;
      This project will provide helpful data on possible replacement treatment in this novel form&#xD;
      of cerebellar degeneration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 17, 2015</start_date>
  <completion_date type="Actual">June 25, 2018</completion_date>
  <primary_completion_date type="Actual">September 17, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double-blind randomised placebo-controlled phase, followed by an open-label phase</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline SARA score at 16 weeks and 40 weeks</measure>
    <time_frame>baseline, 16 weeks, 40 weeks</time_frame>
    <description>improvement of ataxia by SARA scores</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline ICARS score at 16 weeks and 40 weeks</measure>
    <time_frame>baseline, 16 weeks, 40 weeks</time_frame>
    <description>improvement of ataxia by ICARS scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain FDG-PET</measure>
    <time_frame>baseline, 16 weeks, 40 weeks</time_frame>
    <description>improvement of cerebellar hypometabolism</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>SCA38</condition>
  <arm_group>
    <arm_group_label>DHA administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DHA 600 mg/day will be administered for 16 weeks to 5 patients in double blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo administration</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo will be made with the same colour and taste, in softgel as DHA, and will be administered for 16 weeks to 5 patients in double blind.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>DHA</intervention_name>
    <arm_group_label>DHA administration</arm_group_label>
    <arm_group_label>placebo administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mutations p.Gly230Val in ELOVL5 gene&#xD;
&#xD;
          -  Clinical symptoms of ataxia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of fish oil or DHA dietary supplement within 30 days prior the enrollment in the&#xD;
             present trial&#xD;
&#xD;
          -  Evidence of poorly controlled diabetes (defined as hemoglobin A1c &gt; 8% in patients&#xD;
             with diabetes)&#xD;
&#xD;
          -  Average alcohol consumption of more than one drink or equivalent (&gt;12 g) per day or&#xD;
             more than two drinks on any 1 day over the 30 days prior to screening.&#xD;
&#xD;
          -  Serum creatinine level 2.0 mg/dL or greater or currently on dialysis&#xD;
&#xD;
          -  Evidence of drug abuse within 6 months prior to entering the study or during the&#xD;
             screening period&#xD;
&#xD;
          -  Reported poor compliance to drug assumption&#xD;
&#xD;
          -  Bedridden patients (SARA score &gt;23)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Borroni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AO Spedali Civili</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AO Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.telethon.it/donation?gclid=CMGG5cfGgNMCFReNGwod8SkLPQ</url>
    <description>The Telethon Foundation is a leading Italian charity organization investing in the research of rare genetic diseases</description>
  </link>
  <reference>
    <citation>Di Gregorio E, Borroni B, Giorgio E, Lacerenza D, Ferrero M, Lo Buono N, Ragusa N, Mancini C, Gaussen M, Calcia A, Mitro N, Hoxha E, Mura I, Coviello DA, Moon YA, Tesson C, Vaula G, Couarch P, Orsi L, Duregon E, Papotti MG, Deleuze JF, Imbert J, Costanzi C, Padovani A, Giunti P, Maillet-Vioud M, Durr A, Brice A, Tempia F, Funaro A, Boccone L, Caruso D, Stevanin G, Brusco A. ELOVL5 mutations cause spinocerebellar ataxia 38. Am J Hum Genet. 2014 Aug 7;95(2):209-17. doi: 10.1016/j.ajhg.2014.07.001. Epub 2014 Jul 24.</citation>
    <PMID>25065913</PMID>
  </reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>December 28, 2018</last_update_submitted>
  <last_update_submitted_qc>December 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</investigator_affiliation>
    <investigator_full_name>Barbara Borroni</investigator_full_name>
    <investigator_title>Associated Professor of Neurology, MD</investigator_title>
  </responsible_party>
  <keyword>DHA, replacement, treatment, brain PET-FDG, ataxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Spinocerebellar Ataxias</mesh_term>
    <mesh_term>Spinocerebellar Degenerations</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>to share data after study publication</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>March 12, 2019</submitted>
    <returned>June 13, 2019</returned>
    <submitted>June 17, 2019</submitted>
    <returned>August 2, 2019</returned>
    <submitted>August 5, 2019</submitted>
    <returned>September 13, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

